Precigen, Inc. (NASDAQ:PGEN - Get Free Report)'s share price shot up 10.9% during mid-day trading on Wednesday . The stock traded as high as $1.70 and last traded at $1.69. 2,525,199 shares changed hands during trading, an increase of 66% from the average session volume of 1,520,873 shares. The stock had previously closed at $1.52.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on PGEN. Wall Street Zen raised Precigen from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. JMP Securities reaffirmed a "market outperform" rating and set a $6.00 target price on shares of Precigen in a research report on Thursday, June 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Precigen in a research report on Thursday, May 15th.
View Our Latest Analysis on PGEN
Precigen Trading Down 1.9%
The firm has a 50-day moving average price of $1.54 and a 200-day moving average price of $1.53. The stock has a market capitalization of $463.43 million, a PE ratio of -2.80 and a beta of 1.78.
Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. Precigen had a negative return on equity of 279.20% and a negative net margin of 3,728.87%. The company had revenue of $1.34 million during the quarter, compared to analyst estimates of $0.50 million. Sell-side analysts expect that Precigen, Inc. will post -0.32 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Precigen
Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in Precigen in the 4th quarter worth about $27,000. Envestnet Asset Management Inc. increased its holdings in Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 5,915 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in Precigen in the 4th quarter worth about $35,000. Apella Capital LLC purchased a new stake in Precigen in the 1st quarter worth about $40,000. Finally, RPO LLC purchased a new stake in Precigen in the 4th quarter worth about $47,000. Hedge funds and other institutional investors own 33.51% of the company's stock.
Precigen Company Profile
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Further Reading
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access